[go: up one dir, main page]

GT201000153A - Agonistas novedosos de los receptores de glucocorticoides - Google Patents

Agonistas novedosos de los receptores de glucocorticoides

Info

Publication number
GT201000153A
GT201000153A GT201000153A GT201000153A GT201000153A GT 201000153 A GT201000153 A GT 201000153A GT 201000153 A GT201000153 A GT 201000153A GT 201000153 A GT201000153 A GT 201000153A GT 201000153 A GT201000153 A GT 201000153A
Authority
GT
Guatemala
Prior art keywords
glucocorticoid receptors
new agonists
agonists
new
novedous
Prior art date
Application number
GT201000153A
Other languages
English (en)
Inventor
Glossop Paul Alan
Millan David Simon
Price David Anthony
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000153(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000153A publication Critical patent/GT201000153A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A AGONISTAS NOVEDOSOS DEL RECEPTOR DE GLUCOCORTICOIDES Y A PROCEDIMIENTOS E INTERMEDIOS PARA SU PREPARACIÓN. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN ESTOS COMPUESTOS, A SU COMBINACIÓN CON OTRO U OTROS AGENTES TERAPÉUTICOS, ASI COMO A SU USO PARA EL TRATAMIENTO DE UN NÚMERO DE ENFERMEDADES, TRASTORNOS Y AFECCIONES INFLAMATORIAS Y ALÉRGICOS.
GT201000153A 2007-11-30 2010-05-24 Agonistas novedosos de los receptores de glucocorticoides GT201000153A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135407P 2007-11-30 2007-11-30
US5724108P 2008-05-30 2008-05-30
US7955508P 2008-07-10 2008-07-10

Publications (1)

Publication Number Publication Date
GT201000153A true GT201000153A (es) 2012-04-27

Family

ID=40427125

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000153A GT201000153A (es) 2007-11-30 2010-05-24 Agonistas novedosos de los receptores de glucocorticoides

Country Status (32)

Country Link
US (2) US8822439B2 (es)
EP (1) EP2225256B1 (es)
JP (1) JP4686650B2 (es)
KR (1) KR101295998B1 (es)
CN (1) CN101878221B (es)
AP (1) AP2010005267A0 (es)
AR (1) AR069490A1 (es)
AU (1) AU2008331187B2 (es)
BR (1) BRPI0820447A2 (es)
CA (1) CA2706180C (es)
CL (1) CL2008003549A1 (es)
CO (1) CO6280401A2 (es)
CR (1) CR11393A (es)
DK (1) DK2225256T3 (es)
DO (1) DOP2010000161A (es)
EA (1) EA201070535A1 (es)
EC (1) ECSP10010209A (es)
ES (1) ES2399945T3 (es)
GT (1) GT201000153A (es)
IL (1) IL205356A0 (es)
MA (1) MA31867B1 (es)
MX (1) MX2010005861A (es)
NI (1) NI201000090A (es)
NZ (1) NZ585434A (es)
PA (1) PA8805801A1 (es)
PE (1) PE20091072A1 (es)
SV (1) SV2010003580A (es)
TN (1) TN2010000230A1 (es)
TW (1) TW200930378A (es)
UY (1) UY31496A1 (es)
WO (1) WO2009069032A2 (es)
ZA (1) ZA201003439B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524057B1 (en) * 2010-01-15 2016-03-30 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
TW201139369A (en) 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
AR085817A1 (es) * 2011-03-15 2013-10-30 Chiesi Farma Spa Derivados de isoxazolidina
CN103380142A (zh) * 2011-03-15 2013-10-30 奇斯药制品公司 异噁唑烷衍生物
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
AU2014228990B2 (en) * 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3244893A4 (en) 2015-02-18 2019-01-09 Parion Sciences, Inc. SODIUM CHANNEL BLOCKER FOR SKIN DISEASES
CN114617962A (zh) 2016-04-27 2022-06-14 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
PE20190622A1 (es) * 2016-06-02 2019-04-26 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
SG11202004865SA (en) * 2017-12-01 2020-06-29 Abbvie Inc Anti-cd40 antibody drug conjugates
HUE054428T2 (hu) * 2017-12-01 2021-09-28 Abbvie Inc Glükokortikoid receptor agonista és annak immunkonjugátumai
WO2019180150A1 (en) 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
CN109734763A (zh) * 2019-01-20 2019-05-10 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙产品的制备方法
CN109651474A (zh) * 2019-01-20 2019-04-19 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙的新的制备方法
CN109575095A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基醋酸泼尼松龙的制备方法
CN109575097A (zh) * 2019-01-20 2019-04-05 湖南科瑞生物制药股份有限公司 一种16a-羟基泼尼松龙产品的新的制备方法
AR125084A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
CN120463762A (zh) * 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
EP4539888A1 (en) 2022-06-16 2025-04-23 Abbvie Biotherapeutics Inc. Anti-cd19 antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US8232304B2 (en) 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
WO2005044759A2 (en) * 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US20050227927A1 (en) 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis

Also Published As

Publication number Publication date
TN2010000230A1 (fr) 2011-11-11
AR069490A1 (es) 2010-01-27
AU2008331187B2 (en) 2014-04-03
JP4686650B2 (ja) 2011-05-25
CN101878221B (zh) 2014-04-02
KR20100074306A (ko) 2010-07-01
CL2008003549A1 (es) 2009-11-20
ZA201003439B (en) 2011-02-23
JP2011505350A (ja) 2011-02-24
US20140336160A1 (en) 2014-11-13
AP2010005267A0 (en) 2010-06-30
NZ585434A (en) 2012-06-29
ECSP10010209A (es) 2010-06-29
SV2010003580A (es) 2011-03-23
TW200930378A (en) 2009-07-16
US8822439B2 (en) 2014-09-02
PA8805801A1 (es) 2009-07-23
EA201070535A1 (ru) 2010-12-30
AU2008331187A1 (en) 2009-06-04
KR101295998B1 (ko) 2013-08-13
WO2009069032A3 (en) 2009-08-06
CN101878221A (zh) 2010-11-03
US20090227548A1 (en) 2009-09-10
EP2225256A2 (en) 2010-09-08
WO2009069032A2 (en) 2009-06-04
CO6280401A2 (es) 2011-05-20
IL205356A0 (en) 2010-12-30
CR11393A (es) 2010-05-19
DOP2010000161A (es) 2010-07-15
UY31496A1 (es) 2009-07-17
MA31867B1 (fr) 2010-11-01
DK2225256T3 (da) 2013-03-11
ES2399945T3 (es) 2013-04-04
CA2706180C (en) 2012-10-23
MX2010005861A (es) 2010-06-11
HK1144821A1 (en) 2011-03-11
EP2225256B1 (en) 2013-01-09
NI201000090A (es) 2010-10-04
PE20091072A1 (es) 2009-07-23
BRPI0820447A2 (pt) 2015-05-26
CA2706180A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
GT201000153A (es) Agonistas novedosos de los receptores de glucocorticoides
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CL2009000734A1 (es) Compuestos derivados de 4-aminociclohexano sustituido; composicion farmaceutica que comprende a dichos compuestos; y su uso como moduladores del receptor de opioides u y el receptor orl-1 en el tratamiento de la ansiedad, estres, depresion, epilepsia y alzheimer.
UY32675A (es) Nuevos agonistas del receptor de glucocorticoides
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CR10872A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
ECSP088620A (es) 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CR20190379A (es) Moduladores del receptor de estrógeno
CL2008002310A1 (es) Compuestos derivados de benzoil-piperidinas, moduladores del receptor de dopamina d3 y de serotonina 5-ht2a; y uso en el tratamiento y/o prevencion de enfermedades tales como trastornos cognitivos, adiccion a farmacos, depresion y ansiedad.
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona